Last updated: February 15, 2026
What Is the Market Position of ND C: 16729-0169?
ND C 16729-0169 refers to Venclexta (venetoclax), developed by AbbVie in collaboration with Roche. This drug is used primarily to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It also holds approval for acute myeloid leukemia (AML) in specific settings.
It is a BCL-2 inhibitor that induces apoptosis in cancer cells. Since FDA approval in April 2016 for CLL with 17p deletion, Venclexta has become a critical drug in hematologic oncology.
How Competitive Is the Venclexta Market?
Key Competitors
| Drug Name |
Mechanism |
Approvals |
Key Indications |
| Ibrutinib |
BTK inhibitor |
Approved since 2013 |
CLL, SLL, Waldenström's macroglobulinemia, MCL |
| Acalabrutinib |
BTK inhibitor |
Approved since 2019 |
CLL, SLL |
| Obinutuzumab |
Anti-CD20 monoclonal antibody |
Approved since 2013 |
CLL, follicular lymphoma |
| Idelalisib |
PI3Kδ inhibitor |
Approved since 2014 |
CLL, SLL, follicular lymphoma |
Market Size & Trends
- The global hematologic oncology drug market was valued at $10.2 billion in 2022.
- Compound annual growth rate (CAGR) estimated at 8% through 2027.
- Venclexta annually generates approximately $3 billion in revenue globally (IQVIA data 2022).
Adoption & Usage Trends
- Increasing adoption in earlier lines of therapy for CLL due to favorable side-effect profile compared to chemoimmunotherapy.
- Expanding for AML in combination therapies; FDA approved in May 2022 for newly diagnosed AML in patients who are 75 or older or have comorbidities.
- Industry observes a rising shift toward oral targeted therapies as standard of care in hematology.
What Are the Price Trends for Venclexta?
List Price in the United States (2023)
| Formulation |
Price per Unit |
Approximate Annual Cost (Patient) |
| 50 mg tablets |
$400 per tablet |
$146,000 (standard dosing) |
| 100 mg tablets |
$800 per tablet |
$293,000 (standard dosing) |
Cost based on wholesale acquisition prices (WAC).
Pricing Benchmarks & Discounts
- Insurers and pharmacy benefit managers (PBMs) negotiate discounts, considerably reducing out-of-pocket costs.
- Patient assistance programs from AbbVie reduce individual financial burden.
Comparisons with Competitors
- Ibrutinib (Imbruvica) roughly costs $151,000 annually.
- Acalabrutinib (~$134,000).
- Venetoclax’s price remains comparable to other targeted oral agents but is somewhat higher than some monoclonal antibody-based options.
Projections and Future Market Dynamics
Short-term (Next 1-2 years)
- Continued growth driven by approval expansion into AML and combination regimens.
- Expected to reach approximately $3.5 billion in global sales by 2024.
- Entry of biosimilars or trastuzumab biosimilar-like competitors unlikely for at least 3-4 years without significant patent legal developments.
Long-term (Next 5-10 years)
- Market saturation in CLL likely; growth driven by therapeutic line expansion.
- Combination therapies involving venetoclax and other agents (e.g., obinutuzumab, ibrutinib) expected to dominate treatment landscapes.
- Pricing pressures from biosimilar development and payor negotiations could reduce prices by 10-15% in the long term.
Patent Landscape & Legal Factors
- Primary patents expire between 2027-2030 in the U.S.
- Patent litigation and legal challenges could impact exclusivity and pricing.
- Data exclusivity for generics would extend beyond patent expiry, delaying biosimilar entry.
What Is the Regulatory Outlook?
- Continued expansion in indications, including in solid tumors research.
- Orphan drug status and fast track designations could expedite future approvals.
- Post-marketing studies will confirm long-term safety and add indications.
Key Takeaways
- Venclexta is a leading BCL-2 inhibitor with strong market presence in hematological malignancies.
- Market growth driven by approvals for AML and combination therapies.
- Pricing remains high but competitive with similar targeted agents; payor negotiations and assistance programs influence actual patient costs.
- Short-term sales are projected around $3.5 billion globally; long-term growth depends on expanding indications and competitive pressures.
- Patent expirations from 2027 onward could lead to biosimilar competition and price reductions.
5 Frequently Asked Questions
1. When are patent expirations expected for Venclexta?
Patents related to Venclexta are expected to expire between 2027 and 2030, opening potential for biosimilar entry.
2. What are the main competitors to Venclexta in hematological oncology?
Primary competitors include ibrutinib, acalabrutinib, and obinutuzumab. The competitive landscape is defined by mechanism, approval status, and combination potential.
3. How are prices for Venclexta determined?
Prices are set based on wholesale acquisition costs, manufacturer discounts, and negotiations with payors. Assistance programs offset costs for eligible patients.
4. What is the outlook for Venclexta in AML?
FDA approval for newly diagnosed AML in older or unfit patients is recent, opening a new revenue stream with expected growth as combination therapies are studied and adopted.
5. Are biosimilars likely to impact Venclexta’s market?
Yes, starting around 2027, biosimilar competition may emerge, potentially reducing prices and market share, contingent on patent litigation outcomes.
Sources:
[1] IQVIA, 2022 Data; Industry Reports, 2023; FDA approvals and label updates; Company Financials.
